News und Analysen
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
EQS-News: Eckert & Ziegler Receives Award for Professional Training
EQS-News: Eckert & Ziegler Receives Award for Professional Training
EQS-Adhoc: Vita 34 AG: A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor
EQS-Adhoc: Vita 34 AG: A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor
EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
EQS-News: MediClin AG: Thomas Piefke becomes a member of MEDICLIN's Management Board and will be responsible for the post-acute segment in the future
EQS-News: MediClin AG: Thomas Piefke becomes a member of MEDICLIN's Management Board and will be responsible for the post-acute segment in the future
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: M1 Kliniken AG: Market leader for beauty medicine in Germany opens up in the 9th foreign market and prepares market entry in the USA
EQS-News: M1 Kliniken AG: Market leader for beauty medicine in Germany opens up in the 9th foreign market and prepares market entry in the USA
EQS-News: M1 Kliniken AG publishes figures for the first half year 2023:
EQS-News: M1 Kliniken AG publishes figures for the first half year 2023:
EQS-News: Vita 34 stabilizes business development in the second quarter and noticeably improves earnings
EQS-News: Vita 34 stabilizes business development in the second quarter and noticeably improves earnings
EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
EQS-Adhoc: MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year
EQS-Adhoc: MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year
EQS-News: MediClin AG: Higher demand for medical, therapeutic and nursing services led to an increase in sales and earnings in the Group
EQS-News: MediClin AG: Higher demand for medical, therapeutic and nursing services led to an increase in sales and earnings in the Group
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
EQS-News: MediClin AG: MEDICLIN focusses on innovative outpatient concepts in rehabilitation
EQS-News: MediClin AG: MEDICLIN focusses on innovative outpatient concepts in rehabilitation
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result
EQS-News: M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result
EQS-News: Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
EQS-News: Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
EQS-News: Reorganization in the Executive Board of Eckert & Ziegler
EQS-News: Reorganization in the Executive Board of Eckert & Ziegler
EQS-News: Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
EQS-News: Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate